Total Valuation
Edwards Lifesciences has a market cap or net worth of €42.96B. The enterprise value is €49.95K.
Market Cap€42.96B
Enterprise Value€49.95K
Share Statistics
Edwards Lifesciences has 575,800,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding575,800,000
Owned by Insiders0.24%
Owned by Institutions6.21%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)11.40%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee379.23K
Profits Per Employee66.84K
Employee Count16,000
Asset Turnover0.44
Inventory Turnover1.18
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 49.5. Edwards Lifesciences’s PEG ratio is -0.63.
PE Ratio49.5
PS Ratio8.22
PB Ratio4.82
Price to Fair Value4.82
Price to FCF37.34
Price to Operating Cash Flow36.52
PEG Ratio-0.63
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.
Revenue6.07B
Gross Profit4.74B
Operating Income1.64B
Pretax Income1.27B
Net Income1.07B
EBITDA1.43B
Earnings Per Share (EPS)1.84
Cash Flow
In the last 12 months, operating cash flow was 1.07B and capital expenditures -219.80M, giving a free cash flow of 848.60M billion.
Operating Cash Flow1.07B
Free Cash Flow848.60M
Free Cash Flow per Share1.47
Dividends & Yields
Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change9.34%
50-Day Moving Average76.66
200-Day Moving Average72.11
Relative Strength Index (RSI)43.93
Average Volume (3m)37.00
Important Dates
Edwards Lifesciences upcoming earnings date is Oct 28, 2026, After Close (Confirmed).
Last Earnings DateJul 23, 2026
Next Earnings DateOct 28, 2026
Ex-Dividend Date―
Financial Position
Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.81%
Current Ratio3.72
Quick Ratio3.09
Debt to Market Cap0.01
Net Debt to EBITDA-1.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.
Income Tax216.90M
Effective Tax Rate0.17
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 33.31, with an EV/FCF ratio of 35.67.
EV to Sales7.85
EV to EBITDA33.31
EV to Free Cash Flow35.67
EV to Operating Cash Flow29.85
Balance Sheet
Edwards Lifesciences has €3.67B in cash and marketable securities with €0.00 in debt, giving a net cash position of €3.67B billion.
Cash & Marketable Securities€3.67B
Total Debt€0.00
Net Cash€3.67B
Net Cash Per Share€6.38
Tangible Book Value Per Share€12.72
Margins
Gross margin is 77.98%, with operating margin of 26.97%, and net profit margin of 17.69%.
Gross Margin77.98%
Operating Margin26.97%
Pretax Margin20.98%
Net Profit Margin17.69%
EBITDA Margin23.56%
EBIT Margin20.98%
Analyst Forecast
The average price target for Edwards Lifesciences is €90.31, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€90.31
Price Target Upside19.75% Upside
Analyst ConsensusStrong Buy
Analyst Count19
Revenue Growth Forecast6.85%
EPS Growth Forecast6.20%